Beam Therapeutics EPS BEAM

Diluted earnings per share by quarter and over the last twelve months, from 2019.

Beam Therapeutics' earnings per share was −$0.82 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$1.18.

Earnings per share over time

Each fiscal year is the twelve months to its fourth quarter.

Quarter	Ended	EPS	On a year earlier	Last 12 months
Q2 FY26	Jun 30, 2026	−$1.18	n/a	−$0.82
Q1 FY26	Mar 31, 2026	−$0.91	n/a	−$0.64
Q4 FY25	Dec 31, 2025	$2.37	n/a	−$0.96
Q3 FY25	Sep 30, 2025	−$1.10	n/a	−$4.42
Q2 FY25	Jun 30, 2025	−$1.00	n/a	−$4.49
Q1 FY25	Mar 31, 2025	−$1.23	n/a	−$4.60
Q4 FY24	Dec 31, 2024	−$1.09	−162%	−$4.58
Q3 FY24	Sep 30, 2024	−$1.17	n/a	−$1.72
Q2 FY24	Jun 30, 2024	−$1.11	n/a	−$1.77
Q1 FY24	Mar 31, 2024	−$1.21	n/a	−$1.74
Q4 FY23	Dec 31, 2023	$1.77	n/a	−$1.86
Q3 FY23	Sep 30, 2023	−$1.22	n/a	−$4.17

Companies in Biotechnology nearest Beam Therapeutics' size, closest first, today.

Company	EPS, 12 months	Growth
BEAMBeam Therapeutics	−$0.82
ADMAAdma Biologics	$0.70	−18% a year
VCELVericel	$0.46	+283% a year
MGTXMeiraGTx	$0.71
KRYSKrystal Biotech	$7.98	+62% a year
RGENRepligen	$0.73
TECHBIO-TECHNE	$1.15	+150% a year
HALOHalozyme Therapeutics	$3.35	−23% a year
NBIXNeurocrine Biosciences	$6.82	+102% a year
EXELExelixis	$3.18	+53% a year
INCYIncyte	$7.85	+78% a year
Peer median	$2.17